<?xml version='1.0' encoding='utf-8'?>
<document id="18414469"><sentence text="A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours."><entity charOffset="57-69" id="DDI-PubMed.18414469.s1.e0" text="capecitabine" /><entity charOffset="71-77" id="DDI-PubMed.18414469.s1.e1" text="Xeloda" /><pair ddi="false" e1="DDI-PubMed.18414469.s1.e0" e2="DDI-PubMed.18414469.s1.e0" /><pair ddi="false" e1="DDI-PubMed.18414469.s1.e0" e2="DDI-PubMed.18414469.s1.e1" /></sentence><sentence text="This dose escalation study was designed to determine the recommended dose of the multi-targeted cell cycle inhibitor indisulam in combination with capecitabine in patients with solid tumours and to evaluate the pharmacokinetics of the combination"><entity charOffset="147-159" id="DDI-PubMed.18414469.s2.e0" text="capecitabine" /></sentence><sentence text=" Thirty-five patients were treated with indisulam on day 1 of each 21-day cycle" /><sentence text=" Capecitabine was administered two times daily (BID) on days 1-14"><entity charOffset="1-13" id="DDI-PubMed.18414469.s4.e0" text="Capecitabine" /></sentence><sentence text=" Plasma concentrations of indisulam, capecitabine and its three metabolites were determined for pharmacokinetic analysis"><entity charOffset="26-35" id="DDI-PubMed.18414469.s5.e0" text="indisulam" /><entity charOffset="37-49" id="DDI-PubMed.18414469.s5.e1" text="capecitabine" /><pair ddi="false" e1="DDI-PubMed.18414469.s5.e0" e2="DDI-PubMed.18414469.s5.e0" /><pair ddi="false" e1="DDI-PubMed.18414469.s5.e0" e2="DDI-PubMed.18414469.s5.e1" /></sentence><sentence text=" The main dose-limiting toxicity was myelosuppression" /><sentence text=" Hand/foot syndrome and stomatitis were the major non-haematological toxicities" /><sentence text=" The recommended dose was initially established at indisulam 700 mg m(-2) and capecitabine 1250 mg m(-2) BID"><entity charOffset="78-90" id="DDI-PubMed.18414469.s8.e0" text="capecitabine" /></sentence><sentence text=" However, during cycle 2 the recommended dose was poorly tolerated in three patients" /><sentence text=" A dose of indisulam 500 mg m(-2) and capecitabine 1250 mg m(-2) BID proved to be safe at cycle 1 and 2 in nine additional patients"><entity charOffset="38-50" id="DDI-PubMed.18414469.s10.e0" text="capecitabine" /></sentence><sentence text=" Indisulam pharmacokinetics during cycle 1 were consistent with pharmacokinetic data from phase I mono-therapy studies" /><sentence text=" However, exposure to indisulam was remarkably increased at cycle 2 due to a drug-drug interaction between capecitabine and indisulam"><entity charOffset="107-119" id="DDI-PubMed.18414469.s12.e0" text="capecitabine" /><entity charOffset="124-133" id="DDI-PubMed.18414469.s12.e1" text="indisulam" /><pair ddi="false" e1="DDI-PubMed.18414469.s12.e0" e2="DDI-PubMed.18414469.s12.e0" /><pair ddi="false" e1="DDI-PubMed.18414469.s12.e0" e2="DDI-PubMed.18414469.s12.e1" /></sentence><sentence text=" Partial response was confirmed in two patients, one with colon carcinoma and the other with pancreatic carcinoma" /><sentence text=" Seventeen patients had stable disease" /><sentence text=" Indisulam (700 mg m(-2)) in combination with capecitabine (1250 mg m(-2) BID) was well tolerated during the first cycle"><entity charOffset="46-58" id="DDI-PubMed.18414469.s15.e0" text="capecitabine" /></sentence><sentence text=" A dose of indisulam 500 mg m(-2) and capecitabine 1250 mg m(-2) BID was considered safe in multiple treatment cycles"><entity charOffset="38-50" id="DDI-PubMed.18414469.s16.e0" text="capecitabine" /></sentence><sentence text=" The higher incidence of toxicities observed during cycle 2 can be explained by a time-dependent pharmacokinetic drug-drug interaction" /><sentence text="" /></document>